BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.
BiondVax just initiated a phase IIb trial with EU consortium UNISEC. Please see here for more details.
BiondVax’s go-to-market strategy for its lead candidate M-001, universal flu vaccine is to initially obtain regulatory approval as a primer to a pandemic or seasonal vaccine, and following the accumulation of enough data, to gain approval as a universal standalone vaccine.
Learn more about the Flu
Learn about the limitations of today’s vaccines…
Bill Gates discusses the threat from flu…
Featured on Israeli TV
On August 13, BiondVax was featured on the main Israeli news show, Mabat. You can view this (subtitled) segment below.